Zeitschriftenartikel zum Thema „Novartis Campus“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-31 Zeitschriftenartikel für die Forschung zum Thema "Novartis Campus" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Latagliata, Roberto, Isabella Capodanno, Maria Cristina Miggiano, Cristina Bucelli, Francesco Cavazzini, Sabrina Leonetti Crescenzi, Sabina Russo et al. „Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study“. Blood 138, Supplement 1 (05.11.2021): 3617. http://dx.doi.org/10.1182/blood-2021-151538.
Der volle Inhalt der QuelleChiaretti, Sabina, Massimiliano Bonifacio, Roberta Agrippino, Mario Annunziata, Anna Candoni, Cerrano Marco, Michele Cedrone et al. „ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report“. Blood 138, Supplement 1 (05.11.2021): 216. http://dx.doi.org/10.1182/blood-2021-150958.
Der volle Inhalt der QuelleGugliotta, Gabriele, Mario Annunziata, Isabella Capodanno, Davide Rapezzi, Immacolata Attolico, Iolanda Donatella Vincelli, Mario Tiribelli et al. „Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study“. Blood 136, Supplement 1 (05.11.2020): 45–46. http://dx.doi.org/10.1182/blood-2020-141077.
Der volle Inhalt der QuelleTiribelli, Mario, Isabella Capodanno, Maria Cristina Miggiano, Cristina Bucelli, Francesco Cavazzini, Sabrina Leonetti Crescenzi, Sabina Russo et al. „Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study“. Blood 138, Supplement 1 (05.11.2021): 1487. http://dx.doi.org/10.1182/blood-2021-149780.
Der volle Inhalt der QuelleZoller, Frank A., und Roman Boutellier. „Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus“. Drug Discovery Today 18, Nr. 7-8 (April 2013): 318–22. http://dx.doi.org/10.1016/j.drudis.2012.12.012.
Der volle Inhalt der QuelleSciumè, Mariarita, Cristina Papayannidis, Antonio Curti, Antonella Vitale, Sabina Chiaretti, Mario Annunziata, Fabio Giglio et al. „Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study“. Blood 138, Supplement 1 (05.11.2021): 3408. http://dx.doi.org/10.1182/blood-2021-147325.
Der volle Inhalt der QuelleBonifacio, Massimiliano, Chiara Elena, Mariella D'Adda, Luigi Scaffidi, Mairi Pucci, Fiorenza Aprili, Jacqueline Ferrari et al. „Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations“. Blood 136, Supplement 1 (05.11.2020): 43–44. http://dx.doi.org/10.1182/blood-2020-139826.
Der volle Inhalt der QuelleTiribelli, Mario, Roberto Latagliata, Massimo Breccia, Isabella Capodanno, Maria Cristina Miggiano, Francesco Cavazzini, Sabrina Leonetti Crescenzi et al. „Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"“. Blood 136, Supplement 1 (05.11.2020): 35–36. http://dx.doi.org/10.1182/blood-2020-135972.
Der volle Inhalt der QuelleGentile, Massimo, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti et al. „External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study“. Blood 134, Supplement_1 (13.11.2019): 4308. http://dx.doi.org/10.1182/blood-2019-126702.
Der volle Inhalt der QuelleDownton, Teesha, Emma Karlsen, Katharine Cuff, Euan Walpole, Fiona Simpson und Elgene Lim. „Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer“. Cancer Research 83, Nr. 5_Supplement (01.03.2023): OT2–10–05—OT2–10–05. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-10-05.
Der volle Inhalt der QuelleDownton, Teesha, Davendra Segara, Andrew Ong, Janne Bingham, Emma-Kate Carson, Julia Chen, Kate Middleton, Geoffrey Lindeman, Andrew Parker und Elgene Lim. „Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer“. Cancer Research 83, Nr. 5_Supplement (01.03.2023): OT2–01–10—OT2–01–10. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-01-10.
Der volle Inhalt der QuelleRoeker, Lindsey E., Lydia Scarfo, Thomas Chatzikonstantinou, Pau Abrisqueta, Toby A. Eyre, Raul Cordoba, Ana Muntañola Prat et al. „Worldwide Examination of Patients with CLL Hospitalized for COVID-19“. Blood 136, Supplement 1 (05.11.2020): 45–49. http://dx.doi.org/10.1182/blood-2020-136408.
Der volle Inhalt der QuelleGiryes, S., K. Dolnikov, A. Balbir-Gurman, D. Militianu, N. Puchkov und Y. Braun-Moscovici. „AB1028 A SINGLE-CENTER EXPERIENCE WITH TRANSIENT OSTEOPOROSIS – PATIENT CHARACTERISTIC AND APPROACH TO THERAPY.“ Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1806.1–1807. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6032.
Der volle Inhalt der QuelleVisentin, Andrea, Francesca Romana Mauro, Daniela Pietrasanta, Alberto Fresa, Candida Vitale, Stefania Ciolli, Ramona Cassin et al. „Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus“. Blood 136, Supplement 1 (05.11.2020): 30–31. http://dx.doi.org/10.1182/blood-2020-136883.
Der volle Inhalt der QuelleKleinert, S., P. Rapp, F. Schuch, M. Ronneberger, J. Wendler, P. Sternad, F. Popp et al. „AB0494 COGNITIVE IMPAIRMENT IN AXIAL SPONDYLOARTHRITIS?“ Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1274–75. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1353.
Der volle Inhalt der QuelleVitrano, Angela, Giuseppina Calvaruso, Eliana Lai, Grazia Colletta, Alessandra Quota, Calogera Gerardi, Luciana Concetta Rigoli et al. „Survival Comparability Between Thalassemia Major Versus Thalassemia Intermedia“. Blood 126, Nr. 23 (03.12.2015): 2141. http://dx.doi.org/10.1182/blood.v126.23.2141.2141.
Der volle Inhalt der QuelleAumann, Shlomzion, Uria Tsubary, Sarah Israel, Dina Ben Yehuda, David Lavie, Neta Goldschmidt, Vladimir Vainstein et al. „COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic“. Blood 138, Supplement 1 (05.11.2021): 4088. http://dx.doi.org/10.1182/blood-2021-148512.
Der volle Inhalt der QuelleCombe, B., A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campos, H. S. B. Baraf, U. Kumar et al. „THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS“. Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 320–21. http://dx.doi.org/10.1136/annrheumdis-2020-eular.276.
Der volle Inhalt der QuelleSeror, R., G. Baron, M. Camus, D. Cornec, E. Perrodeau, S. J. Bowman, M. Bombardieri et al. „OP0286 DEVELOPMENT AND PRELIMINARY VALIDATION OF THE SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR): A CONSENSUAL COMPOSITE SCORE FOR ASSESSING TREATMENT EFFECT IN PRIMARY SJÖGREN’S SYNDROME“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 189.2–190. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2583.
Der volle Inhalt der QuelleTuttle, J., E. Drescher, J. A. Simon-Campos, P. Emery, M. Greenwald, A. Kivitz, H. Rha, P. Yachi, C. Kiley und A. Nirula. „POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 397.2–397. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3582.
Der volle Inhalt der QuelleBlanco Cáceres, B. A., Á. Andreu-Suárez, M. Valero, D. Benavent, M. Sanz, J. Campos Esteban, O. Rusinovich et al. „POS1574 SAPHO SYNDROME, CLINIC CHARACTERISTICS FROM THE SAPHO-SORCOM COHORT“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 1163–64. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6386.
Der volle Inhalt der QuelleLerma, J. J., A. Gracia, A. Perez, A. Rueda, C. Molina, M. D. Pastor, I. Balaguer Trull et al. „AB0698 REAL CLINICAL PRACTICE IN THE CONTROL OF REPORTED OUTCOMES BY THE PATIENT (PROS) DIAGNOSED WITH PSORIATIC ARTHRITIS AND/OR ANKYLOSING SPONDYLITIS WHO BEGIN TREATMENT WITH SECUKINUMAB. A PROSPECTIVE MULTICENTRIC STUDY.“ Annals of the Rheumatic Diseases 79, Suppl 1 (Juni 2020): 1645.1–1645. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2795.
Der volle Inhalt der QuelleBecker-Capeller, D., und S. Kapsimalakou. „AB0799 Anatomical abnormalities of the lower lumbar spine do not change the course of non-radiological axial spondyloarthritis“. Annals of the Rheumatic Diseases 81, Suppl 1 (23.05.2022): 1526.2–1526. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1653.
Der volle Inhalt der QuelleCamus, Vincent, Alina Berriolo-Riedinger, Justine Lequesne, David Tonnelet, Pierre Decazes, Cédric Rossi, Pierre Sesques et al. „R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers“. Blood 136, Supplement 1 (05.11.2020): 20–21. http://dx.doi.org/10.1182/blood-2020-136600.
Der volle Inhalt der QuelleAtienza-Mateo, B., A. Serrano-Combarro, M. Martin Lopez, S. Castañeda, R. Melero, J. Loarce-Martos, N. Mena-Vázquez et al. „POS0864 EFFECTIVENESS OF ANTIFIBROTICS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 50 PATIENTS IN CLINICAL PRACTICE“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 737.2–737. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5665.
Der volle Inhalt der Quelle„RE(ACT)2014Rare Diseases. 2nd International Congress on Research of Rare and Orphan Diseases. 5th to 8th March 2014, Gehry Building, Novartis Campus, Basel: Abstracts“. Molecular Syndromology 5, Nr. 2 (2014): 87–99. http://dx.doi.org/10.1159/000358504.
Der volle Inhalt der QuelleWalker, David, Alan Kivitz, Yoshiya Tanaka, Susan Lee, Lei Ye, Hao Hu, Franziska Matzkies et al. „P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data“. Rheumatology 60, Supplement_1 (01.04.2021). http://dx.doi.org/10.1093/rheumatology/keab247.129.
Der volle Inhalt der QuelleKRUTKYTE, GABIJA, ARNA MARIE CATHERINE GOERG, CHRISTIAN A. GROB, GUIDO BELDI, ANNA SILVIA WENNING, ROMAN HOVORKA, MALGORZATA E. WILINSKA et al. „268-OR: Perioperative Fully Closed-Loop vs. Standard Insulin Delivery in Adults Undergoing Major Abdominal Surgery—A Two-Center Randomized Controlled Trial“. Diabetes 73, Supplement_1 (14.06.2024). http://dx.doi.org/10.2337/db24-268-or.
Der volle Inhalt der QuelleCampos, Jesus Abraham Simón, Douglas Arbetter, Hugh Montgomery, F. D. Richard Hobbs, Francisco Padilla, Kenneth Kim, Katie Streicher, Alison Templeton, Rolando M. Viani und Mark T. Esser. „1918. Impact of the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) on the Severity and Progression of COVID-19 Symptoms in the Phase 3 TACKLE Trial“. Open Forum Infectious Diseases 9, Supplement_2 (01.12.2022). http://dx.doi.org/10.1093/ofid/ofac492.1545.
Der volle Inhalt der QuelleRichard Hobbs, F. D., Hugh Montgomery, Francisco Padilla, Kenneth Kim, Jesus Abraham Simón Campos, Douglas Arbetter, Kelly W. Padilla et al. „1924. Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial“. Open Forum Infectious Diseases 9, Supplement_2 (01.12.2022). http://dx.doi.org/10.1093/ofid/ofac492.1551.
Der volle Inhalt der QuelleRichard Hobbs, F. D., Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón Campos, Douglas Arbetter, Seth Seegobin, Alexandre Kiazand et al. „529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study“. Open Forum Infectious Diseases 10, Supplement_2 (27.11.2023). http://dx.doi.org/10.1093/ofid/ofad500.598.
Der volle Inhalt der Quelle